Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study

A K Gupta1, N Dlova, P Taborda

  • 1Division of Dermatology, Department of Medicine, Sunnybrook and Womens' College Health Sciences Center (Sunnybrook site), University of Toronto, Toronto, Canada. agupta@execulink.com

Insights

Weekly fluconazole effectively treats tinea capitis in children. This antifungal medication demonstrated high cure rates and a favorable safety profile in a multicenter study.

Area of Science:

  • Dermatology
  • Mycology
  • Pediatrics

Background:

  • Tinea capitis is a common superficial fungal infection of the scalp, particularly in children.
  • Effective and safe treatment options are crucial for managing this condition and preventing its spread.

Purpose of the Study:

  • To evaluate the efficacy and safety of fluconazole administered once weekly for tinea capitis in children.
  • To assess cure rates and adverse effects associated with this treatment regimen.

Main Methods:

  • An open, multicenter evaluation was conducted in Brazil, Canada, and South Africa.
  • Sixty-one children with tinea capitis caused by Trichophyton and Microsporum species received fluconazole 8 mg/kg once weekly.
  • Treatment durations varied based on clinical indication, with follow-up evaluations conducted 8 weeks post-therapy.

Main Results:

  • An overall complete cure rate (clinical and mycological) of 98.4% (60/61 patients) was achieved.
  • High cure rates were observed for both Trichophyton (100%) and Microsporum canis (94.1%) infections.
  • Fluconazole was well-tolerated, with only mild, reversible gastrointestinal complaints in 4.9% of patients and one case of asymptomatic, reversible elevated liver function tests.

Conclusions:

  • Once-weekly fluconazole is an effective and safe treatment for pediatric tinea capitis.
  • The regimen is associated with high patient compliance and a low incidence of adverse events.
  • This dosing strategy offers a viable therapeutic option for managing fungal scalp infections in children.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...